| 000 | 01830 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250512002356.0 | ||
| 264 | 0 | _c19881121 | |
| 008 | 198811s 0 0 eng d | ||
| 022 | _a0006-291X | ||
| 024 | 7 |
_a10.1016/s0006-291x(88)80822-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAuguet, M | |
| 245 | 0 | 0 |
_aEndothelin and Ca++ agonist Bay K 8644: different vasoconstrictive properties. _h[electronic resource] |
| 260 |
_bBiochemical and biophysical research communications _cOct 1988 |
||
| 300 |
_a186-92 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_a3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester _xpharmacology |
| 650 | 0 | 4 |
_aAngiotensin II _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAorta, Thoracic _xdrug effects |
| 650 | 0 | 4 |
_aCalcium _xpharmacology |
| 650 | 0 | 4 |
_aCarbachol _xpharmacology |
| 650 | 0 | 4 |
_aDiltiazem _xpharmacology |
| 650 | 0 | 4 |
_aEgtazic Acid _xpharmacology |
| 650 | 0 | 4 | _aEndothelins |
| 650 | 0 | 4 |
_aGallopamil _xpharmacology |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMuscle Contraction _xdrug effects |
| 650 | 0 | 4 |
_aMuscle, Smooth, Vascular _xdrug effects |
| 650 | 0 | 4 |
_aNifedipine _xpharmacology |
| 650 | 0 | 4 |
_aPeptides _xpharmacology |
| 650 | 0 | 4 |
_aPhenylephrine _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred Strains |
| 650 | 0 | 4 | _aReference Values |
| 650 | 0 | 4 | _aVasoconstrictor Agents |
| 700 | 1 | _aDelaflotte, S | |
| 700 | 1 | _aChabrier, P E | |
| 700 | 1 | _aPirotzky, E | |
| 700 | 1 | _aClostre, F | |
| 700 | 1 | _aBraquet, P | |
| 773 | 0 |
_tBiochemical and biophysical research communications _gvol. 156 _gno. 1 _gp. 186-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0006-291x(88)80822-2 _zAvailable from publisher's website |
| 999 |
_c2466130 _d2466130 |
||